GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Diasorin SpA (WBO:DIAS) » Definitions » EV-to-Revenue

Diasorin SpA (WBO:DIAS) EV-to-Revenue : 4.69 (As of May. 22, 2025)


View and export this data going back to 2020. Start your Free Trial

What is Diasorin SpA EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Diasorin SpA's enterprise value is €5,679 Mil. Diasorin SpA's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 was €1,210 Mil. Therefore, Diasorin SpA's EV-to-Revenue for today is 4.69.

The historical rank and industry rank for Diasorin SpA's EV-to-Revenue or its related term are showing as below:

WBO:DIAS' s EV-to-Revenue Range Over the Past 10 Years
Min: 3.57   Med: 5.91   Max: 15.65
Current: 4.69

During the past 13 years, the highest EV-to-Revenue of Diasorin SpA was 15.65. The lowest was 3.57. And the median was 5.91.

WBO:DIAS's EV-to-Revenue is ranked worse than
66.35% of 211 companies
in the Medical Diagnostics & Research industry
Industry Median: 2.65 vs WBO:DIAS: 4.69

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2025-05-22), Diasorin SpA's stock price is €93.54. Diasorin SpA's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 was €22.36. Therefore, Diasorin SpA's PS Ratio for today is 4.18.


Diasorin SpA EV-to-Revenue Historical Data

The historical data trend for Diasorin SpA's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Diasorin SpA EV-to-Revenue Chart

Diasorin SpA Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.19 7.08 4.82 3.98 5.09

Diasorin SpA Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.16 4.97 4.75 5.09 4.63

Competitive Comparison of Diasorin SpA's EV-to-Revenue

For the Diagnostics & Research subindustry, Diasorin SpA's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Diasorin SpA's EV-to-Revenue Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Diasorin SpA's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Diasorin SpA's EV-to-Revenue falls into.


;
;

Diasorin SpA EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Diasorin SpA's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=5678.836/1209.633
=4.69

Diasorin SpA's current Enterprise Value is €5,679 Mil.
Diasorin SpA's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €1,210 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Diasorin SpA  (WBO:DIAS) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Diasorin SpA's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=93.54/22.36
=4.18

Diasorin SpA's share price for today is €93.54.
Diasorin SpA's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €22.36.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Diasorin SpA EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Diasorin SpA's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Diasorin SpA Business Description

Traded in Other Exchanges
Address
Via Crescentino Snc, Saluggia, Vercelli, ITA, 13040
DiaSorin, headquartered in Italy, is a global provider of in vitro diagnostics, or IVD, which refers to testing done on samples taken from the human body, such as blood and tissue. DiaSorin produces and markets testing reagent kits for immunodiagnostics (about 65% of total sales) and molecular diagnostics (about 20%) and has a total installed base of about 9,000 diagnostic systems. Instruments and other revenue contribute about 15% of total sales. DiaSorin's largest market in 2023 was North America, which accounted for 48% of non-covid revenue, followed by Europe (35%) and the Rest of the World (18%).

Diasorin SpA Headlines

No Headlines